Clinical Scorecard: Case Study: Unraveling EBV-Related Immune Dysregulation in HLH Revealing Multiple Myeloma and Leading to the Development of Aggressive B-Cell Lymphoma

At a Glance

Key Highlights

• HLH can present as the initial manifestation of multiple myeloma.
• EBV viremia was persistent despite treatment for multiple myeloma.
• Anti-PD-1 therapy provided transient suppression of EBV but HLH recurred.
• Aggressive B-cell lymphoma developed in the context of EBV-associated immune dysregulation.
• The patient experienced severe complications from chemotherapy.
• Diagnostic limitations were faced in classifying the lymphoma.

Guideline-Based Recommendations

Diagnosis

• HLH diagnosis requires fulfillment of 5 of 8 HLH-2004 criteria, including fever, splenomegaly, cytopenias, hypertriglyceridemia, and hemophagocytosis.

Management

• Etoposide plus dexamethasone (ED) is recommended for HLH control.

Monitoring & Follow-up

• Regular monitoring of EBV-DNA levels is essential.

Risks

• Chemotherapy-related myelosuppression and sepsis are significant risks.

Patient & Prescribing Data

A 70-year-old female with HLH and multiple myeloma.

Bortezomib and dexamethasone were used to stabilize the patient's condition, with a clear timeline of treatment response.

Clinical Best Practices

• Consider allogeneic hematopoietic stem cell transplantation for relapsed/refractory EBV-associated HLH when eligible.
• Monitor for HLH recurrence in patients with elevated EBV-DNA levels, emphasizing the importance of EBV reactivation monitoring.

Related Resources & Content

• HLH-2004 diagnostic criteria
• EBV and HLH relationship
• PD-1 blockade in HLH